Equities analysts expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to announce sales of $18.60 million for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings. The highest sales estimate is $22.10 million and the lowest is $16.10 million. Ultragenyx Pharmaceutical reported sales of $10.68 million during the same quarter last year, which indicates a positive year over year growth rate of 74.2%. The company is scheduled to announce its next quarterly earnings results on Monday, May 6th.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $99.06 million for the current fiscal year, with estimates ranging from $69.27 million to $127.21 million. For the next financial year, analysts forecast that the business will post sales of $207.34 million, with estimates ranging from $142.30 million to $257.54 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.74) by $0.01. The business had revenue of $16.26 million during the quarter, compared to the consensus estimate of $13.30 million. Ultragenyx Pharmaceutical had a negative return on equity of 35.26% and a negative net margin of 383.75%.

Several equities research analysts recently weighed in on RARE shares. Wedbush reaffirmed an “outperform” rating and set a $88.00 price target on shares of Ultragenyx Pharmaceutical in a report on Monday, January 7th. Cowen reaffirmed a “buy” rating and set a $69.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 26th. Raymond James reaffirmed an “outperform” rating and set a $80.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 22nd. Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 20th. Finally, BidaskClub raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, January 16th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Ultragenyx Pharmaceutical currently has a consensus rating of “Buy” and an average price target of $78.39.

In other Ultragenyx Pharmaceutical news, CFO Shalini Sharp sold 14,800 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $70.00, for a total value of $1,036,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 8.40% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Exane Derivatives purchased a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $36,000. Meeder Asset Management Inc. increased its position in shares of Ultragenyx Pharmaceutical by 321.1% in the first quarter. Meeder Asset Management Inc. now owns 598 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 456 shares in the last quarter. Bank of Montreal Can increased its position in shares of Ultragenyx Pharmaceutical by 100.9% in the fourth quarter. Bank of Montreal Can now owns 1,079 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 542 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $55,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Ultragenyx Pharmaceutical by 16.6% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,924 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 274 shares in the last quarter. Institutional investors and hedge funds own 98.62% of the company’s stock.

Shares of NASDAQ RARE opened at $67.79 on Wednesday. Ultragenyx Pharmaceutical has a 1-year low of $37.44 and a 1-year high of $90.98. The firm has a market cap of $3.40 billion, a P/E ratio of -9.17 and a beta of 2.22.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Featured Story: Cost of Debt

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.